Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Diastika Biotekindo TbkISX:CHEK -0.77%2 EBIT per Share is Rp5.62 as of Jun. 2026. GuruFocus rates ISX:CHEK with a GF Score™ of 2/100. The stock has 1 warning sign investors should review. Among 106 Medical Distribution companies, PT Diastika Biotekindo Tbk ranks worse than 943395.28% on this metric.
PT Diastika Biotekindo Tbk's EBIT per Share for the
three
months ended in Jun. 2026 was Rp1.04.
Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 was Rp5.62.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for PT Diastika Biotekindo Tbk's EBIT per Share or its related term are showing as below:
ISX:CHEK's 3-Year EBIT Growth Rate is not ranked *
in the Medical Distribution industry.
Industry Median: 3.35 * Ranked among companies with meaningful 3-Year EBIT Growth Rate only.
PT Diastika Biotekindo Tbk (ISX:CHEK) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
PT Diastika Biotekindo Tbk EBIT per Share Related Terms
PT Diastika Biotekindo Tbk EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp5.62
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Diastika Biotekindo Tbk (ISX:CHEK) has a EBIT per Share of Rp5.62 as of Jun. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PT Diastika Biotekindo Tbk and its competitors. According to the industry distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 106 companies in the Medical Distribution industry.
Is PT Diastika Biotekindo Tbk's EBIT per Share too high?
PT Diastika Biotekindo Tbk's current EBIT per Share is Rp5.62. Based on the distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 106 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, PT Diastika Biotekindo Tbk has a GF Score™ of 2/100, reflecting its overall financial health beyond just this single metric.
How does PT Diastika Biotekindo Tbk's EBIT per Share compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Diastika Biotekindo Tbk ranks #999999 out of 106 companies for EBIT per Share. This places PT Diastika Biotekindo Tbk in the lower half of its industry. The industry median EBIT per Share is 3.35. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 3.35, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on PT Diastika Biotekindo Tbk and its competitors. For the Medical Distribution industry, the median EBIT per Share is 3.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Diastika Biotekindo Tbk's current EBIT per Share is Rp5.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Diastika Biotekindo Tbk stock overvalued right now?
PT Diastika Biotekindo Tbk (ISX:CHEK) has a current EBIT per Share of Rp5.62. The current EBIT per Share is Rp5.62. PT Diastika Biotekindo Tbk's overall GF Score™ is 2/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For PT Diastika Biotekindo Tbk (ISX:CHEK), the current EBIT per Share is Rp5.62 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AddressJalan Rawagelam V, Kawasan Industri Pulogadung, Block L, No. Kav 11-13, Gedung Etana Lantai 3, Desa/Kelurahan Jatinegara, Kec. Cakung, Kota Adm. Jakarta Timur, Jakarta, IDN, 13930
PT Diastika Biotekindo Tbk is engaged in providing medical and laboratory equipment solutions in Indonesia. It is engaged in the wholesale trading of laboratory equipment, pharmaceutical products, and medical devices for human use. The company is also involved in wholesale trading of radioactive substances and ionizing radiation generators, and undertakes activities related to the testing and/or calibration of medical devices, as well as the inspection of healthcare facilities and infrastructure. Its product offerings mainly include devices like hematology analyzer, pipette, hemoglobin testing system, etc. The company's operating segments are: Diagnostics Group, which generates the maximum revenue, and Life Sciences Group. Geographically, all of its revenue is derived from Indonesia.
2GF Score
Get the complete analysis for ISX:CHEK
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:CHEK has been successfully added to your 
